bluebird bio Inc (NASDAQ:BLUE) – Stock analysts at Cantor Fitzgerald increased their FY2017 earnings per share estimates for bluebird bio in a research report issued on Wednesday. Cantor Fitzgerald analyst E. Piros now anticipates that the biotechnology company will post earnings per share of ($6.78) for the year, up from their previous forecast of ($8.44).

BLUE has been the topic of several other research reports. Jefferies Group LLC reaffirmed a “buy” rating and issued a $88.00 target price on shares of bluebird bio in a report on Friday, March 24th. Zacks Investment Research downgraded shares of bluebird bio from a “hold” rating to a “sell” rating in a report on Tuesday, April 25th. Roth Capital reaffirmed a “neutral” rating and issued a $71.00 target price (down previously from $87.00) on shares of bluebird bio in a report on Monday, February 6th. Maxim Group set a $87.00 target price on shares of bluebird bio and gave the company a “buy” rating in a report on Friday, February 3rd. Finally, Morgan Stanley lifted their target price on shares of bluebird bio from $58.00 to $87.00 and gave the company an “equal weight” rating in a report on Wednesday, March 1st. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the stock. bluebird bio presently has a consensus rating of “Buy” and a consensus price target of $84.36.

Earnings History and Estimates for bluebird bio (NASDAQ:BLUE)

COPYRIGHT VIOLATION NOTICE: This piece of content was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/05/15/bluebird-bio-inc-blue-to-post-fy2017-earnings-of-6-78-per-share-cantor-fitzgerald-forecasts.html.

bluebird bio (NASDAQ:BLUE) opened at 87.50 on Monday. The firm’s market capitalization is $3.58 billion. bluebird bio has a 52-week low of $36.62 and a 52-week high of $100.40. The company’s 50-day moving average is $87.87 and its 200-day moving average is $74.40.

bluebird bio (NASDAQ:BLUE) last posted its earnings results on Wednesday, May 3rd. The biotechnology company reported ($1.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.76) by $0.08. The company had revenue of $6.83 million during the quarter, compared to the consensus estimate of $1.51 million. bluebird bio had a negative net margin of 3,941.72% and a negative return on equity of 30.79%.

In other news, insider Jason Cole sold 3,772 shares of the business’s stock in a transaction that occurred on Tuesday, February 14th. The shares were sold at an average price of $80.01, for a total value of $301,797.72. Following the completion of the transaction, the insider now owns 12,717 shares of the company’s stock, valued at $1,017,487.17. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director John Maraganore sold 13,839 shares of the business’s stock in a transaction that occurred on Friday, March 3rd. The shares were sold at an average price of $85.02, for a total transaction of $1,176,591.78. Following the completion of the transaction, the director now directly owns 5,765 shares of the company’s stock, valued at approximately $490,140.30. The disclosure for this sale can be found here. In the last three months, insiders sold 34,694 shares of company stock valued at $3,038,684. Company insiders own 3.50% of the company’s stock.

Several institutional investors have recently bought and sold shares of BLUE. Berkeley Capital Partners LLC purchased a new position in bluebird bio during the third quarter worth $247,000. Hood River Capital Management LLC bought a new stake in bluebird bio during the third quarter worth about $8,071,000. Sei Investments Co. increased its stake in bluebird bio by 106.7% in the third quarter. Sei Investments Co. now owns 2,515 shares of the biotechnology company’s stock worth $170,000 after buying an additional 1,298 shares during the last quarter. Prudential Financial Inc. bought a new stake in bluebird bio during the third quarter worth about $456,000. Finally, Rhumbline Advisers increased its stake in bluebird bio by 4.4% in the third quarter. Rhumbline Advisers now owns 47,412 shares of the biotechnology company’s stock worth $3,214,000 after buying an additional 2,011 shares during the last quarter.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

5 Day Chart for NASDAQ:BLUE

Receive News & Ratings for bluebird bio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc and related companies with MarketBeat.com's FREE daily email newsletter.